Healthcare Industry News: Elan Corp
News Release - September 11, 2007
Pharmacopeia Announces Senior Additions to Management TeamPharmacopeia Adds Executive Vice President, Corporate Development and Senior Vice President, Chemistry and Preclinical Chemical Development
PRINCETON, N.J., Sept. 11 (HSMN NewsFeed) -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, today announced the appointments of Eric J. Liebler as Executive Vice President, Corporate Development and S. David Kimball, Ph.D., as Senior Vice President, Chemistry and Preclinical Chemical Development.
In this new position, Mr. Liebler will employ his broad experience in strategy and corporate development to refine the Company's progress towards product commercialization, including the identification of opportunities that leverage Pharmacopeia's high-value assets.
Prior to joining Pharmacopeia, Mr. Liebler served most recently as Senior Vice President, Strategic Planning at Questcor Pharmaceuticals and held executive-level positions with Enzon Pharmaceuticals, Elan Corporation, Amarin Pharmaceuticals, and Athena Neurosciences. Mr. Liebler currently serves as Vice Chairman of the Board of Trustees of the American Academy of Neurology Foundation.
"Eric brings expertise in areas that are critical to Pharmacopeia's continued building of our business," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "Together with David, these key additions to our management team are important to sustaining the significant momentum that we have generated."
Dr. Kimball joins the Pharmacopeia team with more than 25 years of experience in drug discovery. As Pharmacopeia's Senior Vice President, Chemistry and Preclinical Chemical Development, Dr. Kimball will be responsible for all aspects of alliance and independent chemistry research and preclinical chemical development from target identification to investigational new drug (IND) submission. Additionally, he will serve as a key participant in the leadership of all alliances.
Dr. Kimball most recently served as Vice President, Medicinal Chemistry at Lexicon Pharmaceuticals, where he successfully directed that company's chemistry effort to discover drug candidates in multiple therapeutic areas, several of which have entered clinical development. In that position, he built and oversaw a department of more than 70 scientists that executed broad- ranging activities including analytical, structural and computational, process and medicinal chemistry. Prior to Lexicon, Dr. Kimball spent nearly 20 years at Bristol-Myers Squibb Pharmaceutical Research Institute. In various research roles at BMS, he oversaw innovative drug discovery and development projects in the areas of cardiovascular disease and oncology.
"Having worked closely with David Kimball for nearly 20 years, I have first-hand knowledge of his exceptional skills as both a leader and as a scientist," said David Floyd, Ph.D., Pharmacopeia's Executive Vice President and Chief Scientific Officer. "David will be an enormous asset to Pharmacopeia as we continue to build our discovery and development pipeline."
Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and three partnered programs in Phase 1 clinical trials targeting oncology and inflammatory diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.
Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Source: Pharmacopeia, Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.